Pfizer Discontinues One Sunitinib Phase 3 Trial In Advanced Breast Cancer; Other Advanced Breast Cancer Trials Continue

News — By on April 6, 2009 at 2:00 am

Pfizer Inc announced the discontinuation of one of its Phase 3 studies based on statistical assessment for futility: the SUN 1107 Phase 3 study of Sutent® (sunitinib malate) in advanced breast cancer. SUN 1107 evaluated single-agent sunitinib versus single-agent capecitabine for the treatment of a broad range of patients with advanced breast cancer after failure of standard treatment.

Please read the complete article and let us know what you think below.

Leave a Reply

Trackbacks

Leave a Trackback